免疫組織化学染色試薬ヒストファイン(1) Webb TR, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 2009 Mar;9(3):331-56.Della Corte CM, et al. Role and targeting of anaplastic lymphoma kinase in cancer. Mol Cancer. 2018 Feb 19;17(1):30.Pulford K, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997 Feb 15;89(4):1394-404.Falini B, et al. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol. 1998 Sep;153(3):875-86.Mossé YP. Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies. Clin Cancer Res. 2016 Feb 1;22(3):546-52.日本肺癌学会バイオマーカー委員会. 肺癌患者におけるALK融合遺伝子検査の手引き 第3.1版. 2019.https://www.haigan.gr.jp/modules/guideline/index.php?content_id=6 (2020年8月確認)中澤 温子. 未分化大細胞型リンパ腫・ALK陽性型. リンパ腫アトラス 第5版. 中村 栄男 他編. 文光堂.東京. 2018; 258-261.Swerdlow SH, et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition. International Agency for Research on Cancer. Lyon. 2017.Falini B, et al. Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. Haematologica. 2009 Jul;94(7):897-900.Zeng Y, et al. Genetics of anaplastic large cell lymphoma. Leuk Lymphoma. 2016;57(1):21-7.Amin HM, et al. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood. 2007 Oct 1;110(7):2259-67. Parrilla Castellar ER, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014 Aug 28;124(9):1473-80.一般社団法人 日本血液学会. 造血器腫瘍診療ガイドライン2018年版. 第Ⅱ章 リンパ腫, 末梢性T細胞リンパ腫(peripheral T-cell lymphoma：PTCL).http://www.jshem.or.jp/gui-hemali/2_7.html#soron (2020年8月確認)Tsuyama N, et al. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. J Clin Exp Hematop. 2017;57(3):120-142.一般社団法人 日本血液学会. 造血器腫瘍診療ガイドライン2018年版. 第Ⅱ章 リンパ腫, ホジキンリンパ腫(Hodgkin lymphoma：HL).http://www.jshem.or.jp/gui-hemali/2_10.html#soron (2020年8月確認)Savage KJ, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008 Jun 15;111(12):5496-504. Fukano R, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial. Cancer Sci. 2020 Dec;111(12):4540-4547. 中外製薬株式会社. ニュースリリース. ［アレセンサ、再発又は難治性の 融合遺伝子陽性の未分化大細胞リンパ腫に対する適応追加の承認を取得, 2020年02月21日］https://www.chugai-pharm.co.jp/news/detail/20200221160002_952.html (2020年8月確認)(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) ALK79出 典
元のページ ../index.html#81